Covered recipient · General Payments record
TIRRELL T JOHNSON
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$12.94
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $12.94 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Genentech USA, Inc. | $12.94 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TIRRELL T JOHNSON
NPI 1518042415 · CMS profile ID 204048
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
ORLANDO, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1518042415?year=2022&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TIRRELL T JOHNSON, NPI 1518042415, CMS profile ID 204048. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518042415?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). TIRRELL T JOHNSON, NPI 1518042415, CMS profile ID 204048. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518042415?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- TIRRELL T JOHNSON, NPI 1518042415, CMS profile ID 204048, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1518042415?year=2022&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $12.94 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Genentech USA, Inc. | $12.94 | 05/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950775959 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,665,235.05 | 404 |
| PY2024 | Principal investigator | $475,494.74 | 62 |
| PY2023 | Principal investigator | $95,270.20 | 17 |
| PY2022 | Principal investigator | $226,118.71 | 15 |
| PY2021 | Principal investigator | $31,342.00 | 7 |
| PY2020 | Principal investigator | $82,456.06 | 7 |
| PY2019 | Principal investigator | $37,669.74 | 6 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
404 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,820.83 | 12/31/2025 | Covered Recipient Teaching Hospital Orlando Health | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOTE 158 | No dispute reported | 06/30/2026 | 1232926287 |
| Principal investigator 1 | PFIZER INC. | $150.00 | 12/23/2025 | Covered Recipient Teaching Hospital Orlando Health | A PHASE 2 STUDY OF CONTINUOUS TALAZOPARIB PLUS INTERMITTENT LOWDOSE TEMOZOLOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY EXTENSIVESTAGE SMALL CELL LUNG CANCER TRIOUS L07 WI235082 | No dispute reported | 06/30/2026 | 1228721661 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,555.00 | 12/22/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175392358 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $289.28 | 12/17/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997780 |
| Principal investigator 1 | Janssen Research & Development, LLC | $810.00 | 12/12/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | No dispute reported | 06/30/2026 | 1175392263 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,495.00 | 12/11/2025 | Covered Recipient Teaching Hospital Orlando Health | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220818356 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,480.00 | 12/08/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175392233 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 12/08/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134673 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24,150.00 | 12/05/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818340 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 12/04/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175392381 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 12/03/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946694 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,250.00 | 12/02/2025 | Covered Recipient Teaching Hospital Orlando Health | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220818354 |
| Principal investigator 1 | Immunocore Limited | $1,000.00 | 12/01/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146051 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,000.00 | 12/01/2025 | Covered Recipient Teaching Hospital Orlando Health | 81990 | No dispute reported | 06/30/2026 | 1252498745 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,322.59 | 12/01/2025 | Covered Recipient Teaching Hospital Orlando Health | 81990 | No dispute reported | 06/30/2026 | 1252498749 |
| Principal investigator 1 | ModernaTX, Inc. | $11,200.50 | 11/28/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971177 |
| Principal investigator 1 | ModernaTX, Inc. | $1,179.00 | 11/28/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971185 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,406.00 | 11/27/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134649 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $561.99 | 11/27/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134651 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $353.70 | 11/27/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134653 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $458.50 | 11/27/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134655 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,323.00 | 11/27/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134657 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,585.00 | 11/27/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134659 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,406.00 | 11/27/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134661 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $561.99 | 11/27/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134663 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $353.70 | 11/27/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134665 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $458.50 | 11/27/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134667 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,323.00 | 11/27/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134669 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $99.56 | 11/27/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134671 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $458.50 | 11/26/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134633 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $458.50 | 11/26/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134635 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,869.20 | 11/24/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818338 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,000.00 | 11/20/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175392257 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $104.94 | 11/19/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220997722 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $299.70 | 11/19/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220997724 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,954.30 | 11/19/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997760 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $43.95 | 11/19/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997762 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $314.82 | 11/19/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997764 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $719.28 | 11/19/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997766 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,285.00 | 11/19/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997768 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,297.78 | 11/19/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997770 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5,063.40 | 11/19/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997772 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1.80 | 11/19/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997774 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $105.00 | 11/19/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997776 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $378.00 | 11/19/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997778 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,450.00 | 11/14/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | No dispute reported | 06/30/2026 | 1175392193 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000.00 | 11/13/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818336 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $32.80 | 11/12/2025 | Covered Recipient Teaching Hospital Orlando Health | 81990 | No dispute reported | 06/30/2026 | 1252498753 |
| Principal investigator 1 | ModernaTX, Inc. | $70,658.13 | 11/12/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946720 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,406.00 | 11/10/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134611 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $353.70 | 11/10/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134613 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,585.00 | 11/10/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134615 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,323.00 | 11/10/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134617 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $561.99 | 11/10/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134619 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,866.40 | 11/06/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175392088 |
| Principal investigator 1 | ModernaTX, Inc. | $6,274.90 | 11/05/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946722 |
| Principal investigator 1 | ModernaTX, Inc. | $4,585.00 | 11/05/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971181 |
| Principal investigator 1 | ModernaTX, Inc. | $3,537.00 | 11/05/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971205 |
| Principal investigator 1 | ModernaTX, Inc. | $917.00 | 11/05/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971235 |
| Principal investigator 1 | ModernaTX, Inc. | $33,601.50 | 11/05/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971243 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $353.70 | 11/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134591 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $561.99 | 11/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134593 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $353.70 | 11/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134595 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,323.00 | 11/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134597 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,585.00 | 11/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134599 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,406.00 | 11/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134601 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $561.99 | 11/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134603 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,323.00 | 11/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134605 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,406.00 | 11/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134607 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,585.00 | 11/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134609 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,110.00 | 11/03/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175392137 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 11/03/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971209 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $355.01 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134519 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $298.29 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134521 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134523 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $163.23 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134525 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134527 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134529 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $272.87 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134531 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $80.56 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134533 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134535 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $298.29 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134537 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $62.88 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134539 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $298.29 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134541 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $163.23 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134545 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $80.56 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134549 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134551 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $165.58 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134553 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134555 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134557 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134559 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $163.23 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134561 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $339.03 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134565 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $355.01 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134567 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $80.56 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134569 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134571 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134573 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134575 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $368.63 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134577 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $298.29 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134579 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $207.77 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134581 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $298.29 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134583 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $163.23 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134585 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134587 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.13 | 10/31/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134589 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $169,225.00 | 10/28/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818330 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,008.00 | 10/28/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818332 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,844.00 | 10/28/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818334 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,825.00 | 10/28/2025 | Covered Recipient Teaching Hospital Orlando Health | 131462 | No dispute reported | 06/30/2026 | 1252498739 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $575.00 | 10/28/2025 | Covered Recipient Teaching Hospital Orlando Health | 131462 | No dispute reported | 06/30/2026 | 1252498747 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $32.80 | 10/28/2025 | Covered Recipient Teaching Hospital Orlando Health | 81990 | No dispute reported | 06/30/2026 | 1252498757 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,400.00 | 10/27/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175392420 |
| Principal investigator 1 | ModernaTX, Inc. | $936.13 | 10/24/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971159 |
| Principal investigator 1 | ModernaTX, Inc. | $41,763.51 | 10/22/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946686 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,100.00 | 10/21/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | No dispute reported | 06/30/2026 | 1175392208 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,000.00 | 10/16/2025 | Covered Recipient Teaching Hospital Orlando Health | 81990 | No dispute reported | 06/30/2026 | 1252498751 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 10/16/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134511 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 10/16/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134513 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,934.60 | 10/15/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818328 |
| Principal investigator 1 | Janssen Research & Development, LLC | $625.00 | 10/10/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175392403 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,450.00 | 10/07/2025 | Covered Recipient Teaching Hospital Orlando Health | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220818350 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,400.00 | 10/07/2025 | Covered Recipient Teaching Hospital Orlando Health | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220818352 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000.00 | 10/06/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818326 |
| Principal investigator 1 | ModernaTX, Inc. | $150.00 | 10/03/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946676 |
| Principal investigator 1 | ModernaTX, Inc. | $12,576.00 | 10/03/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946698 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 10/03/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134489 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 10/03/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134491 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,550.00 | 10/03/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134493 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 10/03/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134495 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 10/03/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134497 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $925.00 | 10/03/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134499 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,175.00 | 10/03/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134501 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $925.00 | 10/03/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134503 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 10/03/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134505 |
| Principal investigator 1 | Immunocore Limited | $1,000.00 | 10/02/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146053 |
| Principal investigator 1 | Immunocore Limited | $1,000.00 | 10/02/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146055 |
| Principal investigator 1 | Immunocore Limited | $1,000.00 | 10/02/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146057 |
| Principal investigator 1 | Immunocore Limited | $13,743.35 | 09/24/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146043 |
| Principal investigator 1 | Immunocore Limited | $1,049.31 | 09/24/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146045 |
| Principal investigator 1 | Immunocore Limited | $3,170.20 | 09/24/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146047 |
| Principal investigator 1 | Immunocore Limited | $1,000.00 | 09/24/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146049 |
| Principal investigator 1 | ModernaTX, Inc. | $4,873.20 | 09/24/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971203 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $458.50 | 09/24/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134457 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,585.00 | 09/24/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134459 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $353.70 | 09/24/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134461 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,323.00 | 09/24/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134463 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $99.56 | 09/24/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134465 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,406.00 | 09/24/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134467 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $561.99 | 09/24/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134469 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,290.33 | 09/16/2025 | Covered Recipient Teaching Hospital Orlando Health | 81990 | No dispute reported | 06/30/2026 | 1252498133 |
| Principal investigator 1 | Immunocore Limited | $575.00 | 09/12/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146029 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 09/12/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946718 |
| Principal investigator 1 | Immunocore Limited | $1,046.24 | 09/10/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146027 |
| Principal investigator 1 | ModernaTX, Inc. | $14,541.00 | 09/10/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946704 |
| Principal investigator 1 | ModernaTX, Inc. | $12,576.00 | 09/10/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946732 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 09/10/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134437 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 09/10/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134439 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,869.20 | 09/08/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818322 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 09/03/2025 | Covered Recipient Teaching Hospital Orlando Health | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220818348 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $625.00 | 09/02/2025 | Covered Recipient Teaching Hospital Orlando Health | 131462 | No dispute reported | 06/30/2026 | 1252498147 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $24,996.25 | 09/02/2025 | Covered Recipient Teaching Hospital Orlando Health | 131462 | No dispute reported | 06/30/2026 | 1252498149 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,500.00 | 09/02/2025 | Covered Recipient Teaching Hospital Orlando Health | 131462 | No dispute reported | 06/30/2026 | 1252498151 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,750.00 | 09/02/2025 | Covered Recipient Teaching Hospital Orlando Health | 81990 | No dispute reported | 06/30/2026 | 1252498165 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,236.00 | 09/01/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392182 |
| Principal investigator 1 | Janssen Research & Development, LLC | $704.00 | 09/01/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392303 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $33,210.40 | 08/31/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma INTerpath-001 | No dispute reported | 06/30/2026 | 1232937432 |
| Principal investigator 1 | Janssen Research & Development, LLC | $460.00 | 08/28/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | No dispute reported | 06/30/2026 | 1175392244 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 08/27/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946724 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 08/27/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946726 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $925.00 | 08/20/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818318 |
| Principal investigator 1 | ModernaTX, Inc. | $12,576.00 | 08/15/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946680 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,500.00 | 08/14/2025 | Covered Recipient Teaching Hospital Orlando Health | 131462 | No dispute reported | 06/30/2026 | 1252498161 |
| Principal investigator 1 | Immunocore Limited | $842.33 | 08/13/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146031 |
| Principal investigator 1 | ModernaTX, Inc. | $10,742.00 | 08/13/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946688 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,000.00 | 08/06/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818320 |
| Principal investigator 1 | ModernaTX, Inc. | $1,572.00 | 08/06/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971173 |
| Principal investigator 1 | ModernaTX, Inc. | $3,276.44 | 08/06/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971191 |
| Principal investigator 1 | ModernaTX, Inc. | $4,000.00 | 08/06/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971193 |
| Principal investigator 1 | ModernaTX, Inc. | $14,934.00 | 08/06/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971207 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 08/06/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971229 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 08/06/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971231 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 08/06/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134403 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,934.60 | 08/04/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818324 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 08/04/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134399 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 08/04/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134401 |
| Principal investigator 1 | Immunocore Limited | $1,000.00 | 08/01/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146023 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,032.26 | 08/01/2025 | Covered Recipient Teaching Hospital Orlando Health | 81990 | No dispute reported | 06/30/2026 | 1252498175 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,930.00 | 08/01/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392170 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,480.00 | 07/29/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392153 |
| Principal investigator 1 | Janssen Research & Development, LLC | $460.00 | 07/29/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392214 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $139.92 | 07/28/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220997718 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $479.52 | 07/28/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220997720 |
| Principal investigator 1 | ModernaTX, Inc. | $1,572.00 | 07/25/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946692 |
| Principal investigator 1 | ModernaTX, Inc. | $18,864.00 | 07/25/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946710 |
| Principal investigator 1 | ModernaTX, Inc. | $11,461.09 | 07/25/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946712 |
| Principal investigator 1 | ModernaTX, Inc. | $20,174.00 | 07/25/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946716 |
| Principal investigator 1 | ModernaTX, Inc. | $1,965.00 | 07/25/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946736 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $393.00 | 07/24/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818316 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,383.62 | 07/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220810470 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,201.00 | 07/22/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392160 |
| Principal investigator 1 | Immunocore Limited | $1,500.00 | 07/21/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146033 |
| Principal investigator 1 | Immunocore Limited | $1,450.00 | 07/21/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146035 |
| Principal investigator 1 | Immunocore Limited | $2,000.00 | 07/21/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146037 |
| Principal investigator 1 | Immunocore Limited | $500.00 | 07/21/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146039 |
| Principal investigator 1 | Immunocore Limited | $1,000.00 | 07/21/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146041 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 07/21/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392127 |
| Principal investigator 1 | Janssen Research & Development, LLC | $28,826.00 | 07/21/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392297 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 07/18/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946702 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 07/18/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946714 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 07/18/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946730 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $625.00 | 07/18/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134389 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 07/18/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134391 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $625.00 | 07/18/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134393 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 07/18/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134395 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 07/16/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946708 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $375.00 | 07/11/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818314 |
| Principal investigator 1 | ModernaTX, Inc. | $458.50 | 07/11/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971183 |
| Principal investigator 1 | ModernaTX, Inc. | $3,930.00 | 07/11/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971197 |
| Principal investigator 1 | ModernaTX, Inc. | $37,335.00 | 07/11/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971239 |
| Principal investigator 1 | Immunocore Limited | $925.00 | 07/09/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146025 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000.00 | 07/08/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818312 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 07/08/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392315 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24,645.60 | 07/07/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818310 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,323.00 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134339 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,585.00 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134341 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,406.00 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134343 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $99.56 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134345 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $99.56 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134347 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $561.99 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134349 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $353.70 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134351 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $458.50 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134353 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $458.50 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134355 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,323.00 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134357 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,406.00 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134359 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $99.56 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134361 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $561.99 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134363 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $353.70 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134365 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $99.56 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134367 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $99.56 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134369 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $458.50 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134371 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $458.50 | 07/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134373 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 07/04/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134327 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 07/04/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134329 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 07/04/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134331 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 07/04/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134333 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 07/04/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134335 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 07/04/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134337 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,280.71 | 07/02/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134325 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,097.86 | 07/01/2025 | Covered Recipient Teaching Hospital Orlando Health | 81990 | No dispute reported | 06/30/2026 | 1252498123 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,424.00 | 07/01/2025 | Covered Recipient Teaching Hospital Orlando Health | 81990 | No dispute reported | 06/30/2026 | 1252498125 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,191.00 | 07/01/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392107 |
| Principal investigator 1 | ModernaTX, Inc. | $29,935.18 | 07/01/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946728 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,264.00 | 06/27/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818308 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,008.00 | 06/25/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818306 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,377.00 | 06/23/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392204 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $353.70 | 06/23/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134255 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $561.99 | 06/23/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134261 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,406.00 | 06/23/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134269 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,323.00 | 06/23/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134271 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,585.00 | 06/23/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134281 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,300.00 | 06/20/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818304 |
| Principal investigator 1 | ModernaTX, Inc. | $7,377.92 | 06/20/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971189 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,116.00 | 06/17/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392120 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,598.00 | 06/17/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392148 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 06/17/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223268726 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $625.00 | 06/16/2025 | Covered Recipient Teaching Hospital Orlando Health | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220818346 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,700.00 | 06/16/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392413 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $353.70 | 06/16/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134173 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $561.99 | 06/16/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134197 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,406.00 | 06/16/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134219 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,323.00 | 06/16/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134229 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,585.00 | 06/16/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184134233 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,794.00 | 06/13/2025 | Non-covered Recipient Entity TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL | A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) | No dispute reported | 06/30/2026 | 1185538132 |
| Principal investigator 1 | ModernaTX, Inc. | $15,700.16 | 06/12/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971227 |
| Principal investigator 1 | ModernaTX, Inc. | $7,443.42 | 06/11/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971225 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 06/11/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971233 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $752.56 | 06/04/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220810468 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 06/04/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971163 |
| Principal investigator 1 | ModernaTX, Inc. | $6,795.00 | 06/04/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971165 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 06/04/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971195 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 06/04/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971213 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,250.00 | 05/27/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818302 |
| Principal investigator 1 | ModernaTX, Inc. | $7,377.92 | 05/23/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971201 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $575.00 | 05/22/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818300 |
| Principal investigator 1 | ModernaTX, Inc. | $3,000.00 | 05/21/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946696 |
| Principal investigator 1 | ModernaTX, Inc. | $107.42 | 05/21/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971221 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $730.21 | 05/20/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220810466 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,400.00 | 05/20/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392143 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,260.00 | 05/19/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | No dispute reported | 06/30/2026 | 1175392114 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,150.00 | 05/19/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | No dispute reported | 06/30/2026 | 1175392310 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,301.20 | 05/19/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | No dispute reported | 06/30/2026 | 1175392366 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $665.00 | 05/19/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223268724 |
| Principal investigator 1 | Immunocore Limited | $842.33 | 05/16/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146021 |
| Principal investigator 1 | ModernaTX, Inc. | $4,873.20 | 05/16/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971223 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,250.00 | 05/15/2025 | Covered Recipient Teaching Hospital Orlando Health | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220818344 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 05/14/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971171 |
| Principal investigator 1 | ModernaTX, Inc. | $230.00 | 05/14/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971217 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,237.48 | 05/12/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134113 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,008.00 | 05/09/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818298 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,454.00 | 05/08/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392274 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,620.00 | 05/08/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | No dispute reported | 06/30/2026 | 1175392292 |
| Principal investigator 1 | ModernaTX, Inc. | $312.04 | 05/07/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971167 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 05/07/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971215 |
| Principal investigator 1 | ModernaTX, Inc. | $1,241.49 | 05/07/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971219 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000.00 | 05/05/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818296 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 05/01/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946684 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 05/01/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946690 |
| Principal investigator 1 | ModernaTX, Inc. | $1,450.00 | 05/01/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946700 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $73.36 | 04/30/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134091 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $282.96 | 04/30/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134093 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $73.36 | 04/30/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184134095 |
| Principal investigator 1 | ModernaTX, Inc. | $3,646.66 | 04/28/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971237 |
| Principal investigator 1 | Janssen Research & Development, LLC | $170.00 | 04/25/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta | No dispute reported | 06/30/2026 | 1175392132 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $867.30 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997726 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $244.65 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997728 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $29.30 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997730 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $2.20 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997732 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $174.90 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997734 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $39.96 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997736 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $255.50 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997738 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $488.56 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997740 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,305.00 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997742 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1.50 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997744 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $9.00 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997746 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $8.80 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997748 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $15.00 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997750 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $56.40 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997752 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $52.50 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997754 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $31.50 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997756 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $50.60 | 04/23/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220997758 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,200.00 | 04/22/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392397 |
| Principal investigator 1 | ModernaTX, Inc. | $17,824.16 | 04/16/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946678 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,575.00 | 04/15/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223268722 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,156.90 | 04/10/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818294 |
| Principal investigator 1 | ModernaTX, Inc. | $3,000.00 | 04/07/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971199 |
| Principal investigator 1 | Immunocore Limited | $1,000.00 | 04/04/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146019 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 04/04/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971187 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000.00 | 04/03/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818292 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,083.00 | 03/24/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818290 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,000.00 | 03/20/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223268718 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $23,503.75 | 03/13/2025 | Covered Recipient Teaching Hospital Orlando Health | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220818342 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,925.00 | 03/10/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818288 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,839.60 | 03/10/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392338 |
| Principal investigator 1 | Immunocore Limited | $633.72 | 03/07/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146017 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 03/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184133961 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 03/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184133963 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 03/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184133965 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 03/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184133967 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 03/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184133969 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 03/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184133971 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 03/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184133973 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,450.00 | 03/07/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223268716 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000.00 | 03/06/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818284 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,469.90 | 03/06/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818286 |
| Principal investigator 1 | ModernaTX, Inc. | $4,873.20 | 03/05/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971169 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,299.05 | 03/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133949 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $379.90 | 03/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133951 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,784.12 | 03/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133953 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $379.90 | 03/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133955 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,784.12 | 03/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133957 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,299.05 | 03/05/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133959 |
| Principal investigator 1 | Immunocore Limited | $842.33 | 03/03/2025 | Non-covered Recipient Entity Orlando Health Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146015 |
| Principal investigator 1 | ModernaTX, Inc. | $17,971.44 | 03/03/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971175 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $451.88 | 03/01/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | MRD Monotherapy, combination of VSV-GP w/ antiPD1 | No dispute reported | 06/30/2026 | 1220737636 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 02/28/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133943 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 02/28/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133945 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 02/28/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133947 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,299.05 | 02/27/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133897 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,784.12 | 02/27/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133899 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $379.90 | 02/27/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133901 |
| Principal investigator 1 | ModernaTX, Inc. | $16,981.46 | 02/21/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946674 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,500.00 | 02/20/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818282 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $786.00 | 02/20/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133883 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,299.05 | 02/20/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133885 |
| Principal investigator 1 | ModernaTX, Inc. | $14,934.00 | 02/19/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971179 |
| Principal investigator 1 | ModernaTX, Inc. | $1,572.00 | 02/19/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971211 |
| Principal investigator 1 | ModernaTX, Inc. | $625.00 | 02/19/2025 | Covered Recipient Teaching Hospital Orlando Health | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252971241 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,230.00 | 02/17/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | No dispute reported | 06/30/2026 | 1175392076 |
| Principal investigator 1 | Janssen Research & Development, LLC | $495.00 | 02/17/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | No dispute reported | 06/30/2026 | 1175392326 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,933.00 | 02/07/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818264 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,479.27 | 02/06/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818276 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,785.00 | 02/06/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818278 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000.00 | 02/06/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818280 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $32,811.00 | 02/06/2025 | Covered Recipient Teaching Hospital Orlando Health | A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma | No dispute reported | 06/30/2026 | 1236000404 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,000.00 | 02/05/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818274 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,195.93 | 02/03/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133865 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $572.47 | 02/03/2025 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1184133867 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $900.00 | 02/01/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818272 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22,879.80 | 01/30/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818270 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $100.00 | 01/29/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818268 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $399.60 | 01/27/2025 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220997716 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,270.00 | 01/27/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392071 |
| Principal investigator 1 | Janssen Research & Development, LLC | $24,913.00 | 01/23/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392268 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 01/23/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175392280 |
| Principal investigator 1 | ModernaTX, Inc. | $11,602.54 | 01/17/2025 | Covered Recipient Teaching Hospital Orlando Health | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252971161 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000.00 | 01/16/2025 | Covered Recipient Teaching Hospital Orlando Health | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma | No dispute reported | 06/30/2026 | 1220818266 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 01/15/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946682 |
| Principal investigator 1 | ModernaTX, Inc. | $18,000.00 | 01/15/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946734 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,750.00 | 01/10/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta | No dispute reported | 06/30/2026 | 1175392331 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,250.00 | 01/10/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta | No dispute reported | 06/30/2026 | 1175392431 |
| Principal investigator 1 | ModernaTX, Inc. | $625.00 | 01/03/2025 | Covered Recipient Teaching Hospital Orlando Health | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors | No dispute reported | 06/30/2026 | 1252946706 |